Numerous clinical trials evaluate the efficacy and safety of abiraterone acetate, primarily targeting prostate cancer indications—including metastatic castration-resistant prostate cancer and advanced adenocarcinoma—as well as congenital adrenal hyperplasia and healthy volunteer cohorts. Spanning early- to late-stage phases with statuses from actively recruiting to completed, terminated, or withdrawn, these studies are sponsored by academic medical institutions and pharmaceutical companies. Additional research within this landscape examines the influence of single nucleotide polymorphisms on outcomes alongside novel combination therapies.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07237269 | RECRUITING | Prostate Cancer |
University of Nebraska |
2026-10-15 | PHASE2 |
| NCT06952803 | RECRUITING | Prostate Cancer |
AstraZeneca |
2025-08-06 | PHASE3 |
| NCT07190300 | RECRUITING | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
Novartis Pharmaceuticals |
2026-01-13 | PHASE1; PHASE2 |
| NCT04175431 | RECRUITING | Prostate Adenocarcinoma |
University of Washington |
2020-09-30 | PHASE2 |
| NCT07005154 | RECRUITING | Prostate Cancer; Metastatic Castration-Resistant Prostate Cancer; Metastatic Hormone Sensitive Prostate Cancer |
Astellas Pharma Global Development, Inc. |
2025-08-19 | PHASE2 |
| NCT06991556 | ACTIVE_NOT_RECRUITING | Metastatic Hormone-sensitive Prostate Cancer |
Novartis Pharmaceuticals |
2025-07-07 | PHASE2 |
| NCT07711002 | NOT_YET_RECRUITING | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
AstraZeneca |
2026-10-01 | PHASE3 |
| NCT05367440 | ACTIVE_NOT_RECRUITING | Metastatic Prostate Cancer |
AstraZeneca |
2022-06-02 | PHASE1; PHASE2 |
| NCT06863272 | RECRUITING | Castration-Resistant Prostatic Cancer; Metastasis |
Merck Sharp & Dohme LLC |
2025-07-03 | PHASE1; PHASE2 |
| NCT06616597 | RECRUITING | Prostate Cancer (Adenocarcinoma); Metastatic Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2025-02-13 | PHASE2 |
| NCT06592924 | RECRUITING | Prostate Cancer (Adenocarcinoma) |
Canadian Cancer Trials Group |
2025-05-28 | PHASE3 |
| NCT06378866 | RECRUITING | Recurrent Castration-Sensitive Prostate Carcinoma; Recurrent Prostate Cancer; Castration-resistant Prostate Cancer; Biochemically Recurrent Prostate Carcinoma |
Mayo Clinic |
2024-06-03 | PHASE2 |
| NCT05404139 | RECRUITING | Metastatic Prostate Cancer |
University Health Network, Toronto |
2023-05-24 | PHASE2 |
| NCT07650240 | NOT_YET_RECRUITING | Recurrent Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8; Castration-Sensitive Prostate Cancer; Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Prostate Cancer; Prostate Adenocarcinoma; Adenocarcinoma of the Prostate; Localized Prostate Carcinoma; Metastatic Prostate Cancer; Metastatic Prostate Adenocarcinoma; Advanced Prostate Cancer; Advanced Prostate Adenocarcinoma |
Mayo Clinic |
2026-07-01 | PHASE2 |
| NCT07570979 | RECRUITING | Metastatic Castration-resistant Prostate Cancer (mCRPC) |
Novartis Pharmaceuticals |
2026-05-25 | PHASE1 |
| NCT07620574 | ENROLLING_BY_INVITATION | Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET); Extra-Pancreatic NET (epNET); Hepatocellular Carcinoma (HCC); Differentiated Thyroid Cancer (DTC); Non-Clear Cell Renal Cell Carcinoma (nccRCC); Colorectal Cancer; Prostate Cancer |
Exelixis |
2026-07-30 | PHASE3 |
| NCT07717268 | RECRUITING | Prostatic Neoplasms, Castration-Resistant |
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic |
2024-05-16 | PHASE2 |
| NCT06632977 | RECRUITING | Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8 |
Alliance for Clinical Trials in Oncology |
2025-02-06 | PHASE2 |
| NCT04221542 | RECRUITING | Prostate Cancer |
Amgen |
2020-03-04 | PHASE1 |
| NCT07213674 | RECRUITING | Metastatic Castration-resistant Prostate Cancer |
Amgen |
2025-11-28 | PHASE3 |
| NCT05705700 | WITHDRAWN | Prostate Cancer |
Masonic Cancer Center, University of Minnesota |
2023-02 | PHASE2 |
| NCT07802704 | NOT_YET_RECRUITING | Neoplasms, Prostate |
GlaxoSmithKline |
2026-09-22 | PHASE3 |
| NCT07751133 | RECRUITING | Prostate Cancer; mHSPC; mCRPC |
University College, London |
2026-08-28 | PHASE3 |
| NCT02960022 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Astellas Pharma Global Development, Inc. |
2016-12-22 | PHASE2 |
| NCT06650579 | RECRUITING | Recurrent Prostate Carcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8 |
Emory University |
2025-01-31 | PHASE3 |
| NCT07611110 | RECRUITING | Metastatic Castration-resistant Prostate Cancer |
AstraZeneca |
2026-05-04 | PHASE3 |
| NCT06844383 | RECRUITING | Prostate Cancer (Adenocarcinoma); mCRPC (Metastatic Castration-resistant Prostate Cancer) |
Prostate Cancer Clinical Trials Consortium |
2026-05-04 | PHASE2 |
| NCT06691984 | ACTIVE_NOT_RECRUITING | Metastatic Castration-resistant Prostate Cancer |
Amgen |
2024-12-09 | PHASE3 |
| NCT06212583 | ACTIVE_NOT_RECRUITING | Prostate Cancer; Oligometastatic Disease |
University of Maryland, Baltimore |
2024-04-17 | PHASE2 |
| NCT07730580 | NOT_YET_RECRUITING | Advanced Prostate Cancer |
Evopoint Biosciences Inc. |
2026-07-13 | PHASE2 |
| NCT06768255 | NOT_YET_RECRUITING | Abiraterone Acetate; MCRPC (metastatic Castration-resistant Prostate Cancer) |
Ding-Wei Ye |
2025-01-30 | PHASE3 |
| NCT06099990 | NOT_YET_RECRUITING | High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) |
Jiangsu HengRui Medicine Co., Ltd. |
2023-10 | PHASE1 |
| NCT07230106 | RECRUITING | Prostate Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2025-12-08 | PHASE2 |
| NCT07641855 | NOT_YET_RECRUITING | Castration-resistant Prostate Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2026-09 | PHASE2; PHASE3 |
| NCT03833921 | RECRUITING | Prostate Cancer Metastatic; Prostate Cancer |
Martha Mims |
2019-05-23 | PHASE2 |
| NCT05137262 | ACTIVE_NOT_RECRUITING | Urothelial Carcinoma; Bladder Cancer |
M.D. Anderson Cancer Center |
2021-10-13 | PHASE2 |
| NCT06136624 | RECRUITING | Prostate Cancer Metastatic |
Merck Sharp & Dohme LLC |
2023-12-31 | PHASE3 |
| NCT07226986 | RECRUITING | PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy |
Novartis Pharmaceuticals |
2025-12-05 | PHASE1; PHASE2 |
| NCT06145308 | RECRUITING | Salivary Gland Carcinoma; Precision Therapy |
Peking Union Medical College |
2023-08-15 | PHASE2 |
| NCT04947254 | RECRUITING | Prostate Carcinoma; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2021-08-05 | PHASE2 |
| NCT06136650 | RECRUITING | Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms |
Merck Sharp & Dohme LLC |
2023-12-18 | PHASE3 |
| NCT07795177 | NOT_YET_RECRUITING | Metastatic Hormone-Sensitive Prostate Cancer |
Anhui Medical University |
2026-10-01 | PHASE2 |
| NCT03678025 | RECRUITING | Castration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 |
SWOG Cancer Research Network |
2018-09-24 | PHASE3 |
| NCT02703623 | ACTIVE_NOT_RECRUITING | Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; PSA Progression; Stage IV Prostate Adenocarcinoma AJCC v7 |
M.D. Anderson Cancer Center |
2016-05-18 | PHASE2 |
| NCT07287150 | RECRUITING | Metastatic Castration-Resistant Prostate Cancer |
Hoffmann-La Roche |
2026-03-11 | PHASE2 |
| NCT07140900 | RECRUITING | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) |
Amgen |
2025-10-07 | PHASE1 |
| NCT07723248 | RECRUITING | Metastatic Castration Resistant Prostate Cancer |
ORIC Pharmaceuticals |
2026-08-03 | PHASE3 |
| NCT06392841 | WITHDRAWN | Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Deleterious HRR Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; BRIP1 Gene Mutation; CHEK2 Gene Mutation; FANCA Gene Mutation; PALB2 Gene Mutation; RAD51B Gene Mutation; RAD54L Gene Mutation |
Qian Qin |
2025-10 | PHASE2 |
| NCT04267887 | ACTIVE_NOT_RECRUITING | Castration-Sensitive Prostate Carcinoma; Metastatic Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8 |
OHSU Knight Cancer Institute |
2020-05-11 | PHASE2 |
| NCT05361915 | SUSPENDED | Prostate Cancer; Prostate Cancer Metastatic |
Sorrento Therapeutics, Inc. |
2025-09 | PHASE2 |
| NCT05422911 | RECRUITING | Metastatic Cancer; Neoplasm, Prostate; Castrate-sensitive; Castrate-sensitive Prostate Cancer |
Sun Pharmaceutical Industries Limited |
2022-08-31 | PHASE2 |
| NCT06832774 | RECRUITING | Prostate Cancer Metastatic Disease |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2025-08-01 | PHASE2 |
| NCT07311694 | RECRUITING | PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2026-02-02 | PHASE3 |
| NCT06520345 | RECRUITING | Metastatic Castration-resistant Prostate Cancer |
Telix Pharmaceuticals (Innovations) Pty Limited |
2024-07-26 | PHASE3 |
| NCT06220864 | RECRUITING | Advanced Solid Tumor |
Synnovation Therapeutics, Inc. |
2024-02-23 | PHASE1 |
| NCT05914116 | RECRUITING | Advanced Solid Tumors |
DualityBio Inc. |
2023-08-17 | PHASE1; PHASE2 |
| NCT05393791 | RECRUITING | Prostatic Neoplasms, Castration-Resistant |
Leiden University Medical Center |
2022-11-10 | PHASE2 |
| NCT06971211 | RECRUITING | Metastatic Castration-resistant Prostate Cancer |
Jianbin Bi |
2024-11-27 | PHASE2 |
| NCT02861573 | ACTIVE_NOT_RECRUITING | Metastatic Castration-Resistant Prostate Cancer |
Merck Sharp & Dohme LLC |
2016-11-17 | PHASE1; PHASE2 |
| NCT07104110 | NOT_YET_RECRUITING | Prostatic Neoplasms |
Qilu Pharmaceutical Co., Ltd. |
2025-10 | PHASE1; PHASE2 |
| NCT06120491 | ACTIVE_NOT_RECRUITING | Metastatic Castration-Sensitive Prostate Cancer |
AstraZeneca |
2023-11-21 | PHASE3 |
| NCT06527690 | WITHDRAWN | Prostate Cancer; Castrate Resistant Prostate Cancer; Homologous Recombination Deficiency |
Latin American Cooperative Oncology Group |
2025-04-30 | PHASE2 |
| NCT06764485 | RECRUITING | Metastatic Castration-resistant Prostate Cancer |
Celgene |
2025-03-13 | PHASE3 |
| NCT05818683 | RECRUITING | Metastatic Castration-resistant Prostate Neoplasms; Metastatic Hormone-sensitive Prostate Cancer |
Janssen Research & Development, LLC |
2023-04-26 | PHASE1 |
| NCT04734730 | RECRUITING | Castration-Sensitive Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 |
City of Hope Medical Center |
2021-05-04 | PHASE2 |
| NCT07112209 | ENROLLING_BY_INVITATION | Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer |
Zhujiang Hospital |
2023-11-06 | |
| NCT04812366 | RECRUITING | Prostate Cancer |
University of British Columbia |
2021-09-21 | PHASE2 |
| NCT06457919 | RECRUITING | Prostate Cancer |
Memorial Sloan Kettering Cancer Center |
2024-06-04 | PHASE1; PHASE2 |
| NCT05413421 | RECRUITING | Metastatic Prostate Cancer |
ORIC Pharmaceuticals |
2022-06-01 | PHASE1 |
| NCT05067140 | ACTIVE_NOT_RECRUITING | Prostate Cancer Metastatic |
Novartis Pharmaceuticals |
2021-09-02 | PHASE1; PHASE2 |
| NCT05593497 | RECRUITING | High-Risk Prostate Cancer |
VA Office of Research and Development |
2024-05-31 | PHASE2 |
| NCT04194554 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
University of Michigan Rogel Cancer Center |
2020-11-06 | PHASE1; PHASE2 |
| NCT06369610 | RECRUITING | Oligometastatic Prostate Carcinoma; Prostate Adenocarcinoma |
Mayo Clinic |
2024-04-22 | PHASE2 |
| NCT06500247 | NOT_YET_RECRUITING | The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer |
Qilu Hospital of Shandong University |
2024-07-31 | PHASE2 |
| NCT06421935 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumor |
EMD Serono Research & Development Institute, Inc. |
2024-08-07 | PHASE1 |
| NCT01786265 | ACTIVE_NOT_RECRUITING | Prostate Adenocarcinoma; Recurrent Prostate Carcinoma |
M.D. Anderson Cancer Center |
2013-02-05 | PHASE2 |
| NCT03902951 | ACTIVE_NOT_RECRUITING | Metastatic Prostate Adenocarcinoma; Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation; Recurrent Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8 |
Jonsson Comprehensive Cancer Center |
2021-03-17 | PHASE2 |
| NCT05406999 | RECRUITING | Neoadjuvant Therapy; High Risk Prostate Cancer; Locally Advanced Prostate Cancer; Intense Endocrine Therapy |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2020-02-01 | PHASE2 |
| NCT07299292 | RECRUITING | Prostate Cancer (Diagnosis) |
SMED Clinical Research |
2025-12-01 | PHASE2 |
| NCT04662580 | ACTIVE_NOT_RECRUITING | Metastatic Prostate Cancer |
Janssen Research & Development, LLC |
2021-05-03 | PHASE1 |
| NCT04691804 | ACTIVE_NOT_RECRUITING | Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Jiangsu HengRui Medicine Co., Ltd. |
2021-03-18 | PHASE3 |
| NCT04633252 | RECRUITING | Cancer Of Prostate; Prostate Neoplasms |
National Cancer Institute (NCI) |
2021-02-23 | PHASE1; PHASE2 |
| NCT07093866 | RECRUITING | mCRPC |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2025-07-20 | PHASE2 |
| NCT06551324 | ACTIVE_NOT_RECRUITING | Metastatic Castrate Resistant Prostate Cancer (mCRPC) |
Pfizer |
2024-10-21 | PHASE3 |
| NCT03903835 | RECRUITING | Metastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
Karolinska Institutet |
2019-02-01 | PHASE3 |
| NCT07198633 | RECRUITING | Advanced Prostate Cancer |
Qilu Pharmaceutical Co., Ltd. |
2025-11-05 | PHASE1; PHASE2 |
| NCT03348670 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair |
2023-08-18 | PHASE2; PHASE3 |
| NCT06173362 | RECRUITING | Advanced Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8 |
University of California, Davis |
2023-11-09 | PHASE2 |
| NCT06894511 | ACTIVE_NOT_RECRUITING | Metastatic Castration Resistant Prostate Cancer (mCRPC) |
Novartis Pharmaceuticals |
2025-09-11 | PHASE2 |
| NCT03821792 | ACTIVE_NOT_RECRUITING | Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Prostate Carcinoma Metastatic in the Bone; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2019-07-22 | PHASE2 |
| NCT06329830 | WITHDRAWN | Metastatic Prostate Cancer; Castration-resistant Prostate Cancer; Metastatic Castration-resistant Prostate Cancer |
Baptist Health South Florida |
2024-10 | PHASE1; PHASE2 |
| NCT04787744 | RECRUITING | Prostate Cancer; Oligometastasis; Oligorecurrence; Recurrent Prostate Cancer; Metastatic Prostate Cancer; De Novo Prostate Cancer |
VA Office of Research and Development |
2021-07-01 | PHASE2; PHASE3 |
| NCT02949284 | ACTIVE_NOT_RECRUITING | Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma |
Rutgers, The State University of New Jersey |
2017-06-20 | PHASE2 |
| NCT01688492 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Memorial Sloan Kettering Cancer Center |
2012-09 | PHASE1; PHASE2 |
| NCT05942001 | RECRUITING | Advanced Prostate Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2023-08-03 | PHASE1 |
| NCT06384222 | ACTIVE_NOT_RECRUITING | High Risk Prostate Carcinoma; Prostate Cancer |
Ivan de Kouchkovsky, MD |
2024-12-09 | PHASE2 |
| NCT04925063 | ACTIVE_NOT_RECRUITING | Metastatic Prostate Cancer |
Sun Yat-sen University |
2021-06-16 | PHASE2 |
| NCT05689021 | TERMINATED | Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8 |
Mayo Clinic |
2024-03-05 | PHASE2 |
| NCT05751941 | ACTIVE_NOT_RECRUITING | Prostate Cancer; Metastatic Prostate Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2023-02-14 | PHASE2 |
| NCT06568094 | RECRUITING | Prostate Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2024-09-25 | PHASE1; PHASE2 |
| NCT07553988 | ACTIVE_NOT_RECRUITING | Metastatic Castration-resistant Prostate Cancer |
R-Pharm International, LLC |
2024-10-24 | PHASE2 |
| NCT03860987 | COMPLETED | Castrate Sensitive Prostate Cancer |
National Cancer Institute (NCI) |
2019-04-30 | PHASE2 |
| NCT04748042 | ACTIVE_NOT_RECRUITING | Prostate Cancer; Castrate Sensitive Prostate Cancer; Oligometastatic Disease |
University of Michigan Rogel Cancer Center |
2021-05-28 | PHASE2 |
| NCT04015622 | ACTIVE_NOT_RECRUITING | Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
British Columbia Cancer Agency |
2020-10-07 | PHASE2 |
| NCT03436654 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Memorial Sloan Kettering Cancer Center |
2018-06-21 | PHASE2 |
| NCT03360721 | TERMINATED | Castration-Resistant Prostate Carcinoma; Prostate Adenocarcinoma Without Neuroendocrine Differentiation; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2018-03-06 | PHASE2 |
| NCT00268476 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Medical Research Council |
2005-07-08 | PHASE2; PHASE3 |
| NCT06582628 | RECRUITING | Metastatic Prostate Cancer |
Fundacion Oncosur |
2024-07-05 | PHASE2 |
| NCT02772588 | COMPLETED | Prostate Cancer |
Memorial Sloan Kettering Cancer Center |
2016-05-12 | PHASE2 |
| NCT03548246 | WITHDRAWN | Congenital Adrenal Hyperplasia |
University of Texas Southwestern Medical Center |
2023-01 | PHASE2 |
| NCT04838899 | RECRUITING | Oligoprogressive; Castration-Resistant Prostate Cancer |
Sunnybrook Health Sciences Centre |
2016-07-16 | |
| NCT05627752 | UNKNOWN | Prostate Cancer; Castrate Resistant Prostate Cancer |
Zhongnan Hospital |
2024-06-01 | PHASE2; PHASE3 |
| NCT07001709 | RECRUITING | Prostate Cancer; Pain Cancer |
Deventer Ziekenhuis |
2024-04-12 | PHASE4 |
| NCT06689163 | RECRUITING | Prostate Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2024-12-11 | PHASE1; PHASE2 |
| NCT06198387 | NOT_YET_RECRUITING | Oligo-metastatic Prostate Carcinoma |
Changhai Hospital |
2024-01-01 | |
| NCT03851640 | RECRUITING | MCRPC |
Hinova Pharmaceuticals Inc. |
2019-04-12 | PHASE3 |
| NCT04262154 | ACTIVE_NOT_RECRUITING | Metastatic Prostate Cancer |
Memorial Sloan Kettering Cancer Center |
2020-03-03 | PHASE2 |
| NCT03568656 | COMPLETED | Metastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cancer; Advanced Solid Tumors |
CellCentric Ltd. |
2018-07-23 | PHASE1; PHASE2 |
| NCT05588609 | TERMINATED | NSCLC Harboring NRG1 Fusion; Metastatic Castration-resistant Prostate Cancer |
Partner Therapeutics, Inc. |
2022-11-17 | PHASE2 |
| NCT03009981 | COMPLETED | Prostate Cancer |
Alliance Foundation Trials, LLC. |
2017-03-06 | PHASE3 |
| NCT05733351 | TERMINATED | Castration-Sensitive Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8 |
Emory University |
2023-08-03 | PHASE1 |
| NCT02807805 | ACTIVE_NOT_RECRUITING | Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer |
Mamta Parikh |
2016-10 | PHASE2 |
| NCT06134271 | UNKNOWN | Metastatic Hormone-Sensitive Prostate Cancer |
Jianbin Bi |
2023-11-15 | PHASE2 |
| NCT03141671 | UNKNOWN | Prostate Cancer |
Dana-Farber Cancer Institute |
2017-11-24 | PHASE2 |
| NCT03007732 | COMPLETED | Prostatic Neoplasms |
David Oh |
2017-05-17 | PHASE2 |
| NCT05707468 | NOT_YET_RECRUITING | Oligometastatic Prostate Carcinoma |
Changhai Hospital |
2024-05-01 | |
| NCT06505278 | UNKNOWN | Prostate Cancer |
Sun Yat-sen University |
2024-08 | PHASE2 |
| NCT04497844 | ACTIVE_NOT_RECRUITING | Metastatic Castration-sensitive Prostate Cancer |
Janssen Research & Development, LLC |
2020-09-23 | PHASE3 |
| NCT05574712 | WITHDRAWN | Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2024-01-01 | PHASE2 |
| NCT03764540 | TERMINATED | Metastatic Prostate Cancer |
Centre hospitalier de l'Université de Montréal (CHUM) |
2019-04-01 | PHASE2 |
| NCT05167175 | UNKNOWN | Prostate Cancer; Prostate Carcinoma; Metastatic Prostate Cancer |
Hongqian Guo |
2022-03-01 | PHASE2 |
| NCT04992026 | COMPLETED | Prostatectomy; Oligometastatic Prostate Cancer; Abiraterone |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2021-01-01 | PHASE2 |
| NCT05276492 | TERMINATED | Prostate Cancer; Prostate Adenocarcinoma; Prostate Neoplasm; Prostate Cancer Metastatic |
University of Chicago |
2023-01-24 | PHASE1 |
| NCT04179864 | TERMINATED | Metastatic Prostate Cancer; Metastatic Castration-resistant Prostate Cancer |
Epizyme, Inc. |
2019-11-18 | PHASE1; PHASE2 |
| NCT04421222 | TERMINATED | Prostate Cancer |
ESSA Pharmaceuticals |
2020-06-23 | PHASE1 |
| NCT05457257 | ACTIVE_NOT_RECRUITING | Metastatic Castration-resistant Prostate Cancer |
AstraZeneca |
2022-07-29 | PHASE4 |
| NCT04493853 | ACTIVE_NOT_RECRUITING | Hormone-Sensitive Prostate Cancer |
AstraZeneca |
2020-07-13 | PHASE3 |
| NCT05204927 | ACTIVE_NOT_RECRUITING | Metastasis From Malignant Tumor of Prostate |
Curium US LLC |
2022-02-14 | PHASE3 |
| NCT03098836 | COMPLETED | Prostate Cancer |
Daniel George, MD |
2017-07-10 | PHASE2 |
| NCT05551117 | TERMINATED | Castration-Resistant Prostatic Cancer; Androgen-Independent Prostatic Cancer; Androgen-Insensitive Prostatic Cancer; Androgen-Resistant Prostatic Cancer; Hormone Refractory Prostatic Cancer; Anal Cancer; Anal Neoplasm; Carcinoma, Squamous Cell of Head and Neck; Head and Neck Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Squamous Cell Carcinoma; Malignant Melanoma; Melanoma; Non-small Cell Lung Cancer; Non-small Cell Carcinoma; Small-cell Lung Cancer; Small Cell Carcinoma |
MacroGenics |
2023-06-13 | PHASE2 |
| NCT05177042 | COMPLETED | Prostate Cancer Metastatic |
Arvinas Androgen Receptor, Inc. |
2022-05-13 | PHASE1 |
| NCT04666129 | COMPLETED | Metastatic Castration-Resistant Prostate Cancer; Metastatic Castration-Sensitive Prostate Cancer; Non-Metastatic Castration-Resistant Prostate Cancer |
Sumitomo Pharma America, Inc. |
2021-02-18 | PHASE1 |
| NCT06060587 | WITHDRAWN | Prostate Cancer |
Northwestern University |
2023-10-19 | PHASE2 |
| NCT04726332 | TERMINATED | Neoplasm Malignant; Epithelial Ovarian Cancer; Triple Negative Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Metastatic Castration-resistant Prostate Cancer |
Exelixis |
2021-02-10 | PHASE1 |
| NCT04926155 | UNKNOWN | Metastatic Prostate Cancer |
Sun Yat-sen University |
2021-06-23 | PHASE2 |
| NCT04446117 | ACTIVE_NOT_RECRUITING | Metastatic Prostate Cancer; Prostate Adenocarcinoma |
Exelixis |
2020-10-19 | PHASE3 |
| NCT03298087 | COMPLETED | Newly Diagnosed Oligometastatic Prostate Cancer |
VA Office of Research and Development |
2018-07-01 | PHASE2 |
| NCT05288166 | ACTIVE_NOT_RECRUITING | Prostatic Neoplasms; Neoplasm Metastasis; Urogenital Neoplasms; Physiological Effects of Drugs; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Androgens; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Abiraterone Acetate; Steroid Synthesis Inhibitors; Cytochrome P-450; Enzyme Inhibitors; Prednisone; Prednisolone; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6 |
Eli Lilly and Company |
2022-04-14 | PHASE3 |
| NCT03777982 | TERMINATED | Prostate Cancer |
Dana-Farber Cancer Institute |
2020-04-20 | PHASE3 |
| NCT05212857 | UNKNOWN | Prostate Cancer |
Fudan University |
2022-04 | PHASE2 |
| NCT05171816 | ACTIVE_NOT_RECRUITING | Metastatic Castration-resistant Prostate Cancer |
AstraZeneca |
2021-06-24 | PHASE3 |
| NCT03419234 | ACTIVE_NOT_RECRUITING | Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma in the Soft Tissue; Prostate Carcinoma Metastatic in the Bone; Stage IV Prostate Adenocarcinoma AJCC v7 |
ECOG-ACRIN Cancer Research Group |
2018-04-26 | PHASE2 |
| NCT03706365 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Eli Lilly and Company |
2018-11-26 | PHASE2; PHASE3 |
| NCT01254864 | COMPLETED | Prostate Cancer |
M.D. Anderson Cancer Center |
2011-03-16 | PHASE2 |
| NCT04139772 | UNKNOWN | Metastatic Castration-resistent Prostate Cancer |
National Cancer Institute, Naples |
2019-09-01 | PHASE3 |
| NCT05223582 | UNKNOWN | High-risk Prostate Cancer; Neoadjuvant Therapy |
Fudan University |
2021-05-01 | PHASE2 |
| NCT04647526 | ACTIVE_NOT_RECRUITING | Metastatic Castration-Resistant Prostate Cancer |
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company |
2021-02-25 | PHASE3 |
| NCT04677855 | TERMINATED | Prostate Cancer |
Pellficure Pharmaceuticals, Inc |
2021-03-30 | PHASE1 |
| NCT04631601 | TERMINATED | Metastatic Castration-resistant Prostate Cancer |
Amgen |
2021-01-15 | PHASE1; PHASE2 |
| NCT03012321 | ACTIVE_NOT_RECRUITING | Prostate Cancer Metastatic Castration-Resistant; Abnormal DNA Repair; Metastatic Prostate Carcinoma; Stage IV Prostate Cancer |
Northwestern University |
2017-01-12 | PHASE2 |
| NCT03414034 | COMPLETED | Metastatic Castration-Resistant Prostate Cancer |
Cardiff Oncology |
2018-08-14 | PHASE2 |
| NCT02218606 | COMPLETED | Prostate Cancer |
Memorial Sloan Kettering Cancer Center |
2014-08 | PHASE2 |
| NCT05156450 | UNKNOWN | Prostatic Neoplasms, Castration-Resistant; Drug Therapy, Combination |
West China Hospital |
2022-01-01 | PHASE2 |
| NCT03939689 | COMPLETED | Metastatic Prostate Cancer; Castration-resistant Prostate Cancer; Prostatic Neoplasm; Cancer of the Prostate; Progressive mCRPC |
Progenics Pharmaceuticals, Inc. |
2019-05-30 | PHASE2 |
| NCT06193993 | ACTIVE_NOT_RECRUITING | Prostate Cancer; Metastatic Cancer; Hormone Sensitive Prostate Cancer; Castration-resistant Prostate Cancer |
National University Hospital, Singapore |
2021-11-30 | PHASE1 |
| NCT05376722 | UNKNOWN | Neoadjuvant Therapy |
Hongqian Guo |
2022-02-22 | PHASE2 |
| NCT04207255 | COMPLETED | Prostate Cancer |
Medical University of South Carolina |
2020-03-27 | PHASE2 |
| NCT03348670 | Active not recruiting | Prostate Cancer |
Han Xu M.D. Ph.D. FAPCR Sponsor-Investigator IRB Chair|Medicine Invention Design Inc |
2023-08-18 | Phase 2|Phase 3 |
| NCT06014853 | Completed | Prostate Cancer |
Bukwang Pharmaceutical|Dyna Therapeutics |
2023-08-10 | Phase 1 |
| NCT05405439 | TERMINATED | Metastatic Castration-resistant Prostate Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2022-08-25 | PHASE1; PHASE2 |
| NCT03934840 | COMPLETED | Prostate Cancer |
Masonic Cancer Center, University of Minnesota |
2019-10-10 | PHASE2 |
| NCT02574910 | TERMINATED | Congenital Adrenal Hyperplasia |
University of Texas Southwestern Medical Center |
2017-08-01 | PHASE1 |
| NCT04108247 | UNKNOWN | Prostate Cancer Castration-resistant Prostate Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2019-09-26 | PHASE1 |
| NCT04628988 | COMPLETED | Prostatic Neoplasms |
Celgene |
2021-07-28 | PHASE1 |
| NCT04844749 | TERMINATED | Metastatic Castration-resistant Prostate Cancer; Androgen Resistant Prostatic Cancer |
Veru Inc. |
2021-06-24 | PHASE3 |
| NCT04879589 | WITHDRAWN | Metastatic Castration-resistant Prostate Cancer |
Syneos Health |
2022-09-01 | PHASE1 |
| NCT01961843 | COMPLETED | Prostate Cancer |
Massachusetts General Hospital |
2014-01-14 | |
| NCT04458311 | TERMINATED | Metastatic Castration Resistant Prostate Cancer |
Institute of Cancer Research, United Kingdom |
2020-12-01 | PHASE1; PHASE2 |
| NCT05737082 | Completed | Healthy |
Hanmi Pharmaceutical Company Limited |
2023-03-30 | Phase 1 |
| NCT04869488 | COMPLETED | Metastatic Castration Resistant Prostate Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2021-07-19 | PHASE2 |
| NCT04291664 | TERMINATED | Prostate Cancer |
DisperSol Technologies, LLC |
2020-01-31 | PHASE1 |
| NCT05549778 | COMPLETED | Castration-resistant Prostate Cancer |
Jiangnan University |
2021-01-06 | PHASE1; PHASE2 |
| NCT03569280 | COMPLETED | Castration-Resistant Prostate Cancer |
Kangpu Biopharmaceuticals, Ltd. |
2019-11-26 | PHASE1 |
| NCT03016741 | ACTIVE_NOT_RECRUITING | Castration-Resistant Prostatic Cancer; Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer; Hormone-Refractory Prostate Cancer |
Northwestern University |
2017-03-31 | PHASE4 |
| NCT04887506 | COMPLETED | Metastatic Castration-resistant Prostate Cancer; Metastatic Castration-sensitive Prostate Cancer; Metastatic Prostate Cancer |
Tavanta Therapeutics |
2021-05-05 | PHASE3 |
| NCT05084859 | TERMINATED | Castration-resistant Prostate Cancer; Non-small Cell Lung Cancer; Colorectal Cancer |
Biosplice Therapeutics, Inc. |
2021-11-03 | PHASE1 |
| NCT03043807 | COMPLETED | Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2017-02-22 | PHASE2 |
| NCT04603833 | UNKNOWN | Prostate Cancer Metastatic |
Jiangsu HengRui Medicine Co., Ltd. |
2020-12-02 | PHASE2 |
| NCT04296578 | WITHDRAWN | Prostate Cancer; Castrate Resistant Prostate Cancer |
Stanford University |
2020-10 | PHASE1 |
| NCT04736108 | UNKNOWN | Prostate Cancer |
West China Hospital |
2021-05 | PHASE2 |
| NCT05295927 | TERMINATED | Prostatic Neoplasms |
Janssen Research & Development, LLC |
2022-03-23 | PHASE1 |
| NCT03649841 | TERMINATED | Castration-Sensitive Prostate Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Prostate Small Cell Neuroendocrine Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 |
University of Washington |
2020-06-29 | PHASE2 |
| NCT02975934 | COMPLETED | Metastatic Castration Resistant Prostate Cancer |
pharmaand GmbH |
2017-06-13 | PHASE3 |
| NCT03511196 | ACTIVE_NOT_RECRUITING | Prostate Cancer; Stage IV Prostate Cancer; Advanced Prostate Cancer; Adenocarcinoma of the Prostate |
H. Lee Moffitt Cancer Center and Research Institute |
2018-09-17 | EARLY_PHASE1 |
| NCT04556617 | TERMINATED | Metastatic Castration-resistant Prostate Cancer |
Opna Bio LLC |
2020-09-21 | PHASE1; PHASE2 |
| NCT02789878 | COMPLETED | Prostate Cancer |
Instituto do Cancer do Estado de São Paulo |
2019-01-24 | PHASE2 |
| NCT02903368 | COMPLETED | Prostate Cancer |
Dana-Farber Cancer Institute |
2016-10-19 | PHASE2 |
| NCT03899467 | COMPLETED | Metastatic Castrate Resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
Suzhou Kintor Pharmaceutical Inc, |
2019-05-30 | PHASE2 |
| NCT03834519 | COMPLETED | Prostatic Neoplasms |
Merck Sharp & Dohme LLC |
2019-05-02 | PHASE3 |
| NCT01780220 | COMPLETED | Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy |
UNICANCER |
2012-12 | PHASE1; PHASE2 |
| NCT02025010 | COMPLETED | Castration-resistant Prostate Cancer |
Dana-Farber Cancer Institute |
2014-01-27 | PHASE2 |
| NCT04179396 | COMPLETED | Metastatic Castration Resistant Prostate Cancer |
pharmaand GmbH |
2019-12-05 | PHASE1 |
| NCT03565835 | COMPLETED | Prostatic Neoplasms |
Montefiore Medical Center |
2018-06-13 | PHASE2 |
| NCT02903160 | COMPLETED | Prostate Cancer |
Icahn School of Medicine at Mount Sinai |
2017-01-13 | PHASE2 |
| NCT02090114 | COMPLETED | Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2014-08-25 | PHASE2 |
| NCT04862091 | COMPLETED | Metastatic Castration-resistant Prostate Cancer (mCRPC) |
Jiangsu HengRui Medicine Co., Ltd. |
2021-04-23 | PHASE2 |
| NCT04577833 | ACTIVE_NOT_RECRUITING | Prostatic Neoplasms |
Janssen Research & Development, LLC |
2020-11-13 | PHASE1 |
| NCT03748641 | ACTIVE_NOT_RECRUITING | Castration-Resistant Prostatic Cancer |
Janssen Research & Development, LLC |
2019-01-25 | PHASE3 |
| NCT04477512 | COMPLETED | Metastatic Hormone Refractory Prostate Cancer |
Washington University School of Medicine |
2021-02-19 | PHASE1 |
| NCT03449719 | UNKNOWN | Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone |
Lorenzo Livi |
2018-05-01 | |
| NCT03431350 | ACTIVE_NOT_RECRUITING | Prostatic Neoplasms, Castration-Resistant |
Janssen Research & Development, LLC |
2018-03-02 | PHASE2 |
| NCT04102124 | TERMINATED | Prostate Cancer; Castration-resistant Prostate Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2019-04-08 | PHASE2 |
| NCT01957436 | ACTIVE_NOT_RECRUITING | Metastatic Prostate Cancer |
UNICANCER |
2013-11-13 | PHASE3 |
| NCT03587285 | UNKNOWN | Prostatic Neoplasms |
Guangzhou University of Traditional Chinese Medicine |
2018-09-23 | PHASE1; PHASE2 |
| NCT03732820 | ACTIVE_NOT_RECRUITING | Metastatic Castration-resistant Prostate Cancer |
AstraZeneca |
2018-10-31 | PHASE3 |
| NCT02913196 | COMPLETED | Prostate Cancer Metastatic |
Weill Medical College of Cornell University |
2016-12-30 | PHASE1 |
| NCT02106507 | COMPLETED | Prostate Cancer |
Memorial Sloan Kettering Cancer Center |
2014-04 | PHASE1 |
| NCT04087174 | COMPLETED | Prostate Cancer |
AstraZeneca |
2019-08-05 | PHASE1 |
| NCT03999515 | TERMINATED | Castration-Resistant Prostate Carcinoma; Double-Negative Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 |
University of Washington |
2020-04-27 | PHASE2 |
| NCT02543255 | COMPLETED | Prostate Cancer |
University Health Network, Toronto |
2016-09 | PHASE2 |
| NCT03279250 | COMPLETED | Prostate Adenocarcinoma; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2017-10-13 | PHASE2 |
| NCT03458247 | COMPLETED | Prostate Cancer |
Assistance Publique - Hôpitaux de Paris |
2018-06-22 | PHASE2 |
| NCT01517802 | COMPLETED | Metastatic Castration-resistant Prostate Cancer; Metastatic Breast Cancer |
Janssen Research & Development, LLC |
2012-03-28 | PHASE3 |
| NCT04839055 | UNKNOWN | Castration-resistant Prostate Cancer |
Jiangnan University |
2021-03-18 | PHASE1; PHASE2 |
| NCT04356430 | UNKNOWN | Prostate Cancer |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2019-04-01 | PHASE2 |
| NCT04071262 | COMPLETED | Advanced Cancer |
Eli Lilly and Company |
2019-12-20 | PHASE1 |
| NCT03480646 | COMPLETED | Metastatic Castration Resistant Prostate Cancer (mCRPC) |
Constellation Pharmaceuticals |
2017-11-15 | PHASE1; PHASE2 |
| NCT02160353 | COMPLETED | High Risk Localised Prostate Carcinoma |
Cancer Trials Ireland |
2015-07-09 | PHASE2 |
| NCT02740985 | COMPLETED | Advanced Solid Malignancies; Non-Small Cell Lung Cancer (NSCLC); Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC); Colorectal Carcinoma (CRC) |
AstraZeneca |
2016-06-17 | PHASE1 |
| NCT03173859 | WITHDRAWN | Prostatic Neoplasms, Castration-Resistant |
University of Athens |
2018-01 | PHASE2 |
| NCT03770455 | TERMINATED | Metastatic Castration-resistant Prostate Cancer |
Jodi Layton, MD |
2019-01-25 | PHASE2 |
| NCT03295565 | COMPLETED | Prostate Cancer Metastatic; Metastasis |
The Netherlands Cancer Institute |
2017-05-07 | PHASE2; PHASE3 |
| NCT03878524 | TERMINATED | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent Myelodysplastic Syndrome; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Myeloproliferative Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Chronic Myelomonocytic Leukemia; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Myelodysplastic Syndrome; Refractory Myelodysplastic/Myeloproliferative Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Plasma Cell Myeloma; Refractory Primary Myelofibrosis; Refractory Small Lymphocytic Lymphoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma |
OHSU Knight Cancer Institute |
2020-04-01 | PHASE1 |
| NCT03356444 | UNKNOWN | Prostate Cancer; Castration-resistant Prostate Cancer; Drug |
West China Hospital |
2017-11 | PHASE2 |
| NCT02730975 | COMPLETED | Prostate Cancer |
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
2014-05-12 | PHASE1 |
| NCT01751451 | COMPLETED | Prostate Cancer |
Memorial Sloan Kettering Cancer Center |
2012-12-18 | PHASE2 |
| NCT01858441 | COMPLETED | Pharmacogenetic Study |
Centre Antoine Lacassagne |
2013-04 | |
| NCT03148795 | COMPLETED | Prostate Cancer |
Pfizer |
2017-07-04 | PHASE2 |
| NCT04735913 | UNKNOWN | Abiraterone Acetate; Gene Polymorphism; Pharmacokinetic; Metabolic Analysis; Plasma Concentration |
Zhongnan Hospital |
2020-05-05 | EARLY_PHASE1 |
| NCT03150056 | TERMINATED | Solid Tumours |
GlaxoSmithKline |
2017-07-18 | PHASE1 |
| NCT02036060 | COMPLETED | Metastatic Prostate Cancer |
Spanish Oncology Genito-Urinary Group |
2014-02-07 | PHASE2 |
| NCT03002220 | COMPLETED | Prostate Cancer |
MedSIR |
2016-12-21 | PHASE2 |
| NCT02254785 | UNKNOWN | Metastatic Castration-Resistant Prostatic Cancer |
British Columbia Cancer Agency |
2014-10 | PHASE2 |
| NCT03145285 | UNKNOWN | Cushing Syndrome; Adrenocortical Carcinoma |
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
2017-04-18 | PHASE2 |
| NCT03072238 | COMPLETED | Metastatic Prostate Cancer |
Hoffmann-La Roche |
2017-06-30 | PHASE3 |
| NCT01503229 | COMPLETED | Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Adenocarcinoma |
University of Washington |
2012-12 | PHASE2 |
| NCT02125357 | COMPLETED | Metastatic Castration-Resistant Prostate Cancer |
British Columbia Cancer Agency |
2014-09 | PHASE2 |
| NCT03110588 | WITHDRAWN | Metastatic Prostate Cancer |
University of Alabama at Birmingham |
2018-05-09 | PHASE1 |
| NCT04295161 | COMPLETED | Pharmacokinetics |
Zentiva, k.s. |
2019-06-25 | PHASE1 |
| NCT03418324 | COMPLETED | Prostate Cancer |
Cedars-Sinai Medical Center |
2018-03-05 | PHASE2 |
| NCT02867852 | COMPLETED | Salivary Glands Tumors |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2015-03 | PHASE2 |
| NCT01576172 | COMPLETED | Castration-Resistant Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer AJCC v7 |
National Cancer Institute (NCI) |
2012-03-30 | PHASE2 |
| NCT02204072 | COMPLETED | Prostatic Neoplasms, Castration-Resistant |
Boehringer Ingelheim |
2014-11-11 | PHASE1 |
| NCT02867020 | COMPLETED | Prostate Cancer |
Latin American Cooperative Oncology Group |
2017-10-11 | PHASE2 |
| NCT01940276 | COMPLETED | Prostate Cancer |
Duke University |
2013-10 | PHASE2 |
| NCT02991911 | COMPLETED | Metastatic Castration Resistant Prostate Cancer |
MedImmune LLC |
2017-01-06 | PHASE1 |
| NCT02429193 | COMPLETED | Castration-resistant Prostate Cancer |
University Health Network, Toronto |
2016-03 | PHASE2 |
| NCT02415621 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2015-04-13 | EARLY_PHASE1 |
| NCT03827473 | TERMINATED | Castration-Sensitive Prostate Carcinoma; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer; Stage IVA Prostate Cancer; Stage IVB Prostate Cancer |
University of Utah |
2019-02-08 | PHASE2 |
| NCT02924766 | COMPLETED | Prostatic Neoplasms |
Janssen Research & Development, LLC |
2016-10-03 | PHASE1 |
| NCT02987543 | COMPLETED | Metastatic Castration-resistant Prostate Cancer |
AstraZeneca |
2017-02-06 | PHASE3 |
| NCT03093272 | TERMINATED | Prostate Cancer |
Dana-Farber Cancer Institute |
2017-06-23 | PHASE2 |
| NCT02077634 | COMPLETED | Prostate Cancer |
Universität des Saarlandes |
2014-05 | PHASE2 |
| NCT01884285 | COMPLETED | Advanced Castrate-resistant Prostate Cancer CRPC; Squamous Non-Small Cell Lung Cancer sqNSCLC; Triple Negative Breast Cancer TNBC |
AstraZeneca |
2013-07-09 | PHASE1 |
| NCT02485691 | COMPLETED | Prostate Cancer Metastatic |
Sanofi |
2015-11-09 | PHASE4 |
| NCT02883166 | COMPLETED | Prostate Cancer |
Radboud University Medical Center |
2016-08 | PHASE1 |
| NCT02711137 | TERMINATED | Solid Tumors |
Incyte Corporation |
2016-05-18 | PHASE1; PHASE2 |
| NCT02849990 | COMPLETED | Stage III Prostate Adenocarcinoma AJCC v7; Stage III Prostate Cancer AJCC v7; Stage IV Prostate Adenocarcinoma AJCC v7; Stage IV Prostate Cancer AJCC v7 |
University of Washington |
2017-03-09 | PHASE2 |
| NCT02445976 | COMPLETED | Prostate Cancer |
Innocrin Pharmaceutical |
2015-05 | PHASE2 |
| NCT01949337 | UNKNOWN | Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer |
Alliance for Clinical Trials in Oncology |
2014-01-22 | PHASE3 |
| NCT02217566 | COMPLETED | Prostatic Neoplasms |
Janssen Research & Development, LLC |
2014-09-23 | PHASE2 |
| NCT02379390 | TERMINATED | Prostate Cancer Metastatic |
Sanofi |
2015-06-17 | PHASE2 |
| NCT02257736 | ACTIVE_NOT_RECRUITING | Prostatic Neoplasms |
Aragon Pharmaceuticals, Inc. |
2014-11-26 | PHASE3 |
| NCT04056754 | COMPLETED | Metastatic Castration Resistant Prostate Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2014-07-16 | PHASE3 |
| NCT02962284 | COMPLETED | Metastatic Prostate Cancer |
Sun Pharmaceutical Industries Limited |
2016-11 | PHASE2 |
| NCT03261336 | TERMINATED | Castration-resistant Prostate Cancer |
Donald Trump, MD |
2017-01-06 | PHASE2 |
| NCT02043678 | COMPLETED | Prostatic Neoplasms |
Bayer |
2014-03-30 | PHASE3 |
| NCT01650194 | COMPLETED | Metastatic Castration-Resistant Prostate Cancer |
Astellas Pharma Global Development, Inc. |
2012-07-09 | PHASE2 |
| NCT02268175 | COMPLETED | Prostate Adenocarcinoma; Prostate Cancer; High Risk Prostate Cancer |
Dana-Farber Cancer Institute |
2014-10 | PHASE2 |
| NCT02405858 | COMPLETED | Metastatic Castration-Resistant Prostate Cancer |
Janssen Pharmaceutical K.K. |
2015-04-10 | PHASE4 |
| NCT04863105 | COMPLETED | Healthy Volunteers |
The Affiliated Hospital of Qingdao University |
2017-11-24 | PHASE1 |
| NCT01677897 | COMPLETED | Metastatic Prostate Cancer |
Kantonsspital Graubünden |
2013-08 | PHASE2 |
| NCT02887976 | COMPLETED | Prostate Cancer |
GU Research Network, LLC |
2016-09 | PHASE3 |
| NCT01972217 | COMPLETED | Metastatic Castration-resistant Prostate Cancer |
AstraZeneca |
2014-04-01 | PHASE2 |
| NCT01543776 | COMPLETED | Castration-resistant Prostate Cancer; Stage IV Prostate Cancer |
University of Chicago |
2012-01 | PHASE2 |
| NCT01717053 | COMPLETED | Prostate Cancer |
Duke University |
2014-01-17 | PHASE2 |
| NCT01946165 | COMPLETED | Prostate Cancer |
M.D. Anderson Cancer Center |
2013-10-31 | PHASE2 |
| NCT02049190 | UNKNOWN | Prostate Cancer; Metastatic Prostate Cancer; Androgen-independent Prostate Cancer; Recurrent Prostate Cancer |
Arno Therapeutics |
2014-02 | PHASE1; PHASE2 |
| NCT01681433 | TERMINATED | Prostate Cancer; Metastatic Castrate-Resistant Prostate Cancer; PSA |
Costantine Albany |
2012-12 | PHASE2 |
| NCT01994590 | TERMINATED | Prostate Cancer |
M.D. Anderson Cancer Center |
2014-05-19 | PHASE2 |
| NCT02380313 | WITHDRAWN | Cancer |
GlaxoSmithKline |
2015-10 | PHASE1 |
| NCT01553188 | COMPLETED | Prostatic Neoplasms; Prostate Cancer; Neoplasm, Prostate; Neoplasm,Prostatic |
National Cancer Institute (NCI) |
2012-02-08 | PHASE2 |
| NCT02737332 | COMPLETED | Prostate Cancer |
Sun Pharmaceutical Industries Limited |
2016-03-21 | PHASE2 |
| NCT01637402 | COMPLETED | Castration Resistant Prostate Cancer |
Terence Friedlander, MD |
2013-03-13 | PHASE2 |
| NCT02215161 | TERMINATED | Castration Levels of Testosterone; Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma in the Soft Tissue; Prostate Carcinoma Metastatic in the Bone; PSA Progression; Stage IV Prostate Adenocarcinoma AJCC v7 |
University of California, San Francisco |
2014-09-02 | PHASE2 |
| NCT02656615 | TERMINATED | Prostate Cancer |
Aurelius Omlin |
2016-01 | PHASE2 |
| NCT01845792 | TERMINATED | Prostate Cancer |
University of Colorado, Denver |
2013-07 | PHASE2 |
| NCT01591122 | COMPLETED | Prostate Cancer |
Janssen Research & Development, LLC |
2012-03-27 | PHASE3 |
| NCT01309672 | COMPLETED | Prostate Cancer |
SWOG Cancer Research Network |
2011-08-09 | PHASE2 |
| NCT01995513 | COMPLETED | Prostate Cancer |
Pfizer |
2013-10-22 | PHASE4 |
| NCT01715285 | COMPLETED | Prostate Neoplasms |
Janssen Research & Development, LLC |
2013-02-12 | PHASE3 |
| NCT01771458 | COMPLETED | Reccurent/Metastatic Solid Tumor Disease |
Institut Curie |
2012-10 | PHASE2 |
| NCT02758132 | TERMINATED | Prostate Cancer |
University of Hawaii |
2016-03-01 | PHASE2 |
| NCT02928432 | COMPLETED | Prostate Cancer |
Centro Nacional de Investigaciones Oncologicas CARLOS III |
2013-06 | PHASE2 |
| NCT02034552 | COMPLETED | Prostatic Neoplasms |
Bayer |
2014-03-07 | PHASE2 |
| NCT02123758 | ACTIVE_NOT_RECRUITING | Prostatic Neoplasms; Metastatic Castration-Resistant Prostate Cancer |
Aragon Pharmaceuticals, Inc. |
2014-07-09 | PHASE1 |
| NCT00755885 | COMPLETED | Breast Cancer |
Cancer Research UK |
2008-10 | PHASE1; PHASE2 |
| NCT02116582 | COMPLETED | Metastatic Castration-Resistant Prostate Cancer |
Astellas Pharma Europe B.V. |
2014-05-23 | PHASE4 |
| NCT01487863 | COMPLETED | Prostate Cancer Metastatic; Hormone Refractory Prostate Cancer; Castration-resistant Prostate Cancer |
Dendreon |
2011-12 | PHASE2 |
| NCT01685125 | UNKNOWN | Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer |
University of Southern California |
2012-09 | PHASE2 |
| NCT01735396 | TERMINATED | Prostate Cancer |
Icahn School of Medicine at Mount Sinai |
2012-12 | PHASE2 |
| NCT01828476 | TERMINATED | Prostate Cancer |
Rutgers, The State University of New Jersey |
2013-06 | PHASE2 |
| NCT02130947 | WITHDRAWN | Metastatic Castration Resistant Prostate Cancer (mCRPC) |
UNC Lineberger Comprehensive Cancer Center |
2014-04 | |
| NCT01393730 | COMPLETED | Prostate Cancer |
Mary-Ellen Taplin, MD |
2011-09 | PHASE2 |
| NCT01981707 | TERMINATED | Castration-resistant Prostate Cancer |
University Hospital, Grenoble |
2013-12 | PHASE2; PHASE3 |
| NCT02097303 | COMPLETED | Prostate Cancer |
Carolina Research Professionals, LLC |
2014-03 | PHASE2 |
| NCT01485861 | COMPLETED | Prostate Cancer |
Genentech, Inc. |
2012-01-11 | PHASE1; PHASE2 |
| NCT01023061 | COMPLETED | Adenocarcinoma of the Prostate; Stage II Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer |
University of Washington |
2010-03 | PHASE2 |
| NCT01842321 | COMPLETED | Breast Cancer |
UNICANCER |
2013-07 | PHASE2 |
| NCT01634061 | COMPLETED | Castration-resistant Prostate Cancer |
Novartis Pharmaceuticals |
2012-09 | PHASE1 |
| NCT01867710 | COMPLETED | Prostate Cancer |
Janssen Pharmaceutica N.V., Belgium |
2013-07-16 | PHASE2 |
| NCT01848067 | COMPLETED | Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2013-08-14 | PHASE1; PHASE2 |
| NCT02159690 | WITHDRAWN | Prostate Cancer; Localized Prostate Cancer |
Kenneth Pienta, MD |
2014-09 | PHASE2 |
| NCT01574937 | COMPLETED | Prostate Cancer |
Dana-Farber Cancer Institute |
2012-04-03 | PHASE1 |
| NCT01741753 | TERMINATED | Prostate Cancer |
Dana-Farber Cancer Institute |
2012-11 | PHASE1 |
| NCT01995058 | TERMINATED | Prostate Cancer; Castration Resistant Prostate Cancer; Prostatic Neoplasms |
Exelixis |
2014-02 | PHASE2 |
| NCT02230046 | COMPLETED | Healthy |
Janssen Research & Development, LLC |
2014-10 | PHASE1 |
| NCT01756638 | COMPLETED | Prostate Cancer |
Janssen Research & Development, LLC |
2012-06-06 | PHASE2 |
| NCT01186484 | COMPLETED | Prostatic Neoplasms |
Janssen Pharmaceutical K.K. |
2010-06-01 | PHASE1 |
| NCT01795703 | COMPLETED | Prostate Cancer |
Janssen Research & Development, LLC |
2012-06 | PHASE2 |
| NCT01605227 | COMPLETED | Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms |
Exelixis |
2012-07 | PHASE3 |
| NCT01381874 | COMPLETED | Metastatic ER+ Her2- Breast Cancer; Postmenopausal |
Janssen Research & Development, LLC |
2011-08-24 | PHASE2 |
| NCT01511536 | COMPLETED | Prostate Cancer |
Sanofi |
2012-03 | PHASE1; PHASE2 |
| NCT01685268 | COMPLETED | Prostate Cancer |
Astex Pharmaceuticals, Inc. |
2012-09 | PHASE1; PHASE2 |
| NCT01695135 | COMPLETED | Prostate Neoplasms |
Janssen Research & Development, LLC |
2012-08-09 | PHASE3 |
| NCT01913015 | TERMINATED | Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer |
OHSU Knight Cancer Institute |
2013-07 | PHASE1 |
| NCT01400555 | COMPLETED | Prostate Neoplasms; Prostate Cancer |
Cougar Biotechnology, Inc. |
2011-09-01 | PHASE1 |
| NCT01792687 | COMPLETED | Prostate Cancer |
Aragon Pharmaceuticals, Inc. |
2013-02-05 | PHASE1 |
| NCT00887198 | COMPLETED | Prostate Cancer |
Janssen Research & Development, LLC |
2009-04-28 | PHASE3 |
| NCT01314118 | COMPLETED | Prostate Cancer; Prostatic Neoplasm |
Janssen Biotech, Inc. |
2011-05-04 | PHASE2 |
| NCT01814865 | WITHDRAWN | Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer |
British Columbia Cancer Agency |
2013-05 | PHASE2 |
| NCT01717898 | TERMINATED | Castrate-resistant Prostate Cancer |
Charles Ryan |
2013-01-31 | PHASE1; PHASE2 |
| NCT01897389 | COMPLETED | Healthy Volunteers |
Janssen Research & Development, LLC |
2013-07 | PHASE1 |
| NCT01873001 | COMPLETED | Healthy Volunteers |
Janssen Research & Development, LLC |
2013-05 | PHASE1 |
| NCT01424930 | COMPLETED | Prostate Neoplasms; Prostate Cancer |
Janssen-Ortho Inc., Canada |
2011-10 | PHASE2 |
| NCT01088529 | COMPLETED | Prostate Cancer |
Cougar Biotechnology, Inc. |
2009-12 | PHASE2 |
| NCT01495910 | COMPLETED | 21-hydroxylase Deficiency |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2011-12 | PHASE1 |
| NCT01685983 | COMPLETED | Prostate Cancer |
Janssen Research & Development, LLC |
2011-08-30 | PHASE2 |
| NCT01199146 | COMPLETED | Prostate Cancer |
University of California, San Francisco |
2010-09-10 | PHASE2 |
| NCT00473746 | COMPLETED | Prostate Neoplasms |
Janssen Research & Development, LLC |
2006-06 | PHASE1; PHASE2 |
| NCT01678573 | COMPLETED | Healthy |
Janssen Research & Development, LLC |
2012-07 | PHASE1 |
| NCT01516047 | COMPLETED | Hepatic Impairment |
Janssen Research & Development, LLC |
2012-01 | PHASE1 |
| NCT00544440 | COMPLETED | Prostate Neoplasms |
Janssen Research & Development, LLC |
2007-10 | PHASE2 |
| NCT01640093 | COMPLETED | Healthy Participants |
Janssen Research & Development, LLC |
2012-05 | PHASE1 |
| NCT01575587 | COMPLETED | Pharmacology |
Janssen Research & Development, LLC |
2012-01 | PHASE1 |
| NCT00600535 | COMPLETED | Prostate Neoplasms |
Cougar Biotechnology, Inc. |
2007-07 | PHASE1 |
| NCT01655147 | COMPLETED | Healthy |
Janssen Research & Development, LLC |
2012-01 | PHASE1 |
| NCT00924469 | COMPLETED | Prostate Cancer |
Janssen Research & Development, LLC |
2009-11 | PHASE2 |
| NCT01588782 | COMPLETED | Healthy Volunteers |
Janssen Research & Development, LLC |
2012-01 | PHASE1 |
| NCT00485303 | COMPLETED | Prostatic Neoplasms; Prostate Cancer |
Cougar Biotechnology, Inc. |
2007-06 | PHASE2 |
| NCT00474383 | COMPLETED | Prostate Neoplasms |
Cougar Biotechnology, Inc. |
2006-11 | PHASE2 |
| NCT01362764 | COMPLETED | Healthy Volunteers |
Cougar Biotechnology, Inc. |
2011-05 | PHASE1 |
| NCT00638690 | COMPLETED | Prostatic Neoplasms |
Cougar Biotechnology, Inc. |
2008-05 | PHASE3 |
| NCT01017939 | COMPLETED | Prostate Neoplasms |
Janssen Research & Development, LLC |
2010-01 | PHASE1 |
| NCT02001571 | COMPLETED | Prostate Cancer |
Cougar Biotechnology, Inc. |
2009-08 | PHASE1 |
| NCT01715259 | COMPLETED | Renal Insufficiency |
Cougar Biotechnology, Inc. |
2009-08 | PHASE1 |
| NCT00910754 | COMPLETED | Prostate Neoplasms |
Janssen Research & Development, LLC |
2009-05 | PHASE1 |
| NCT01798628 | COMPLETED | Healthy Volunteers |
Cougar Biotechnology, Inc. |
2009-09 | PHASE1 |
| NCT01664728 | COMPLETED | Prostate Neoplasms |
Janssen Research & Development, LLC |
2007-04 | PHASE1 |
| NCT00473512 | COMPLETED | Prostatic Neoplasms |
Cougar Biotechnology, Inc. |
2005-11 | PHASE1; PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-08-19)
Check the
Abiraterone Acetate
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Abiraterone Acetate Solubility in DMSO
- Abiraterone Acetate Stock Solution
- Abiraterone Acetate Storage
- Abiraterone Acetate Stability
- Abiraterone Acetate Molecular Weight
- Abiraterone Acetate SMILES
- Abiraterone Acetate CAS Number
- Abiraterone Acetate Chemical Structure (2D and 3D)
- Abiraterone Acetate SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.